Enhanced Malaria Vaccine Compositions and Methods

The inventive concept relates to improved compositions and methods for generating an immune response to treat or prevent malaria, addressing limitations of existing vaccine compositions and methods.

The original patent disclosed compositions and methods for generating an immune response to malaria using recombinant MVA viral vectors. However, these compositions and methods had limitations, such as reactogenicity and limited immunogenicity. The new inventive concept addresses these limitations by introducing adjuvants, cytokine expression, and targeted immune cell activation to enhance immunogenicity and reduce reactogenicity.

The new inventive concept encompasses four main aspects: (1) a method for generating an immune response to malaria using a recombinant MVA viral vector encoding a Plasmodium falciparum immunogenic polypeptide, formulated with an adjuvant to enhance immunogenicity and reduce reactogenicity; (2) a system for preventing or treating malaria, comprising a vaccine composition including the recombinant MVA viral vector and a device for administering the vaccine composition in a controlled and targeted manner; (3) a recombinant MVA viral vector engineered to express a cytokine that enhances immune response and reduces adverse reactions; and (4) a method for boosting an immune response to malaria using the recombinant MVA viral vector designed to target specific immune cells and enhance their activation and proliferation.

The new claims introduce novel features, such as adjuvant formulation, cytokine expression, and targeted immune cell activation, which are not present in the original patent. These features provide a significant improvement over the existing compositions and methods, making the new inventive concept non-obvious and novel.

Alternative embodiments of the inventive concept may include using different adjuvants, cytokines, or immune cell targets. Variations of the system may include different devices for administering the vaccine composition or different formulations of the recombinant MVA viral vector.

The enhanced malaria vaccine compositions and methods have significant commercial potential in the vaccine industry, particularly in regions where malaria is prevalent. The targeted and controlled administration of the vaccine composition using a device may also appeal to healthcare providers and patients seeking more effective and safer treatments.